Article Text

Download PDFPDF

4CPS-146 ‘Real world’ experience ofelexacaftor/tezacaftor/ivacaftor in the treatment of cystic fibrosis: effectiveness and safety evaluation
Free
  1. C Fernandez Cuerva,
  2. JD Paradas Palomo,
  3. T Chinchilla Alarcon,
  4. I Muñoz Castillo
  1. Hospital Regional Universitario de Málaga, Servicio de Farmacia, Málaga, Spain

Abstract

Background and Importance Cystic fibrosis (CF) is a life-limiting recessive genetic disorder caused by pathogenic variants in the CFTR (cystic fibrosis transmembrane conductance regulator) gene, resulting in increased viscosity and difficult mucus clearance. Introduction of elexacaftor (ELX)/tezacaftor(TEZ)/ivacaftor(IVA) to clinical practice has brought a change in the clinical approach since they modulate CFTR.

Aim and Objectives To assess effectiveness and security of ELX/TEZ/IVA in patients on a tertiary hospital.

Material and Methods Observational, retrospective study carried out between March 2020 and September 2022, including all adult patients treated with ELX/TEZ/IVA+IVA in our hospital.

Variables included: age, sex, age of diagnose, pulmonary function: measured with % pFEV1 (median percent predicted forced expiratory volume in 1 second) and pulmonary exacerbations; treatment adjustment, adverse events and treatment suspension.

Data were collected from electronic medical records and pharmacy dispensing programs.

Thirty-one patients were included: male 45% (n=14), median of 31 years old (rank 17-45), median age of diagnosis of 4 months (0-38). Before taking ELE/TEZ/IVA+IVA, 45% (n=14) patients received TEZ/IVA+IVA as CFTR modulator; 55% (n=17) did not receive any CFTR modulator. Median length of ELX/TEZ/IVA+IVA treatment at the moment of the analysis was 9.43 months (4.5-31.4).

% pFEV1 during treatment augmented in 83% patients (n=26), slightly decreased in 13% (n=3) and did not vary in 1 patient. Two patients (6.5%) presented pulmonary exacerbations that required antibiotic treatment but not hospital admission.

Two patients (6.5%) required ELX/TEZ/IVA+IVA adjustment: one due to interactions with potent CYP3A4 inhibitors and other because of hepatic insufficiency (Child–Pugh B). Nine (29%) patients presented an increase of transaminase and/or bilirubin in clinical analysis: one patient temporarily discontinued therapy and one suspended treatment definitely.

Conclusion and Relevance The introduction of ELEX/TEZ/IVA to CF treatment has been a hopeful advance that has shown in our population to have a good safety profile -which can be managed with regular check-ups- and with a good efficacy profile, achieving an increase of % pFVE1in a short time.

References and/or Acknowledgements No conflict of interest.

Conflict of Interest No conflict of interest

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.